Ligand activation of peroxisome proliferator-activated receptor-β/δ suppresses liver tumorigenesis in hepatitis B transgenic mice
- 1 July 2016
- journal article
- research article
- Published by Elsevier in Toxicology
- Vol. 363-364, 1-9
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute of the National Institutes of Health (CA140369, CA124533)
This publication has 78 references indexed in Scilit:
- Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonistProceedings of the National Academy of Sciences, 2012
- The role of peroxisome proliferator-activated receptors in carcinogenesis and chemopreventionNature Reviews Cancer, 2012
- Modulation of gastrointestinal inflammation and colorectal tumorigenesis by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ)Drug Discovery Today: Disease Mechanisms, 2011
- Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF ExpressionCell, 2010
- Regulation of Wnt/β‐catenin pathway by cPLA2α and PPARδJournal of Cellular Biochemistry, 2008
- Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in miceBiochemical and Biophysical Research Communications, 2008
- PPARδ regulates multiple proinflammatory pathways to suppress atherosclerosisProceedings of the National Academy of Sciences, 2008
- Peroxisome proliferator-activated receptor-β/δ protects against chemically induced liver toxicity in miceHepatology, 2007
- PPARβ/δ selectively induces differentiation and inhibits cell proliferationCell Death & Differentiation, 2005
- Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infectionCancer, 2003